A shadow economy for unapproved slimming drugs is being driven by social media fitness personalities and sellers on communication apps, based on new investigations.
Experimental Drug Acquiring Traction Online
Retatrutide, which is still in clinical trials, is being promoted by online personalities for its alleged fat-burning properties. Followers are encouraged to message these accounts privately for supplier links, while also receiving promotional offers.
Thriving Commerce on Social Networks
Additionally, a robust market exists on messaging services, where groups with thousands of members share “before and after” photos, injection guides and assertions of next-day UK delivery. Vendors market the drug there before directing buyers to other platforms for purchases.
Understanding Retatrutide
This medication is an experimental injection created by US drugmaker Eli Lilly. The drug affects three intestinal hormones – GLP-1, GIP and glucagon. Early trials indicate it could assist individuals lose up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the successor to Ozempic.
Healthcare Professionals Voice Worries
However, doctors and pharmacists have warned that the sale of what remains an unapproved drug in the UK is a cause for concern and could result in individuals injecting substances of uncertain source.
Several professionals stated the demand for the experimental drug could be linked to the increasing price of approved slimming products such as Mounjaro.
Legal Status and Enforcement
Selling retatrutide on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed medication that cannot be marketed or supplied for human use under the British medical regulations.
Several content creators try to sidestep the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and supply can still breach medicines, marketing, and consumer regulations, potentially leading to fines, legal action or prison.
Platform Reaction and Material Removal
Based on the social media company, the platform has removed violative content and banned associated hashtags and query recommendations. The organization said it was dedicated to maintaining the service secure and investing in strengthening enforcement strategies.
Online Marketplace Activities
Research also discovered communities with up to 9,000 participants marketing retatrutide using the platform's integrated search feature, which operates like a public directory. Typing “retatrutide” immediately displays channels with numerous of users, filled with images of weight loss, positive reviews and detailed instructions for preparing or administering at residence.
Within minutes of entering one community, a seller shared contact information, where the majority of purchases take place. The vendor sent an instruction manual and promised delivery within two days. When asked whether the substance was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. Not one asked about body mass, medical conditions or past usage.
Product Details and Pricing
Within these communities, posts display dark colored packages with Royal Mail labels, claiming to include new batches. One communication read: “It took eight of us to load them this morning.”
Buyers can select between powder vials, mixed at residence with sterile water, or pre-filled injectors typically sold at £160 for 20mg. When asked how much time a injector should be used, sellers give conflicting answers ranging from a few weeks to “depends on your body”.
Service Moderation and Safety Measures
A representative for the messaging service stated it regularly monitored harmful content on its platform including material that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Warnings
“Individuals are administering materials they cannot confirm. Even if the research behind this drug is sound, these digital products may not include what they advertise,” said a pharmacy expert, the director of pharmaceutical services at Chemist4U.
A medical professional of an online medical service linked the surge in interest to recent cost increases for authorized slimming medications such as Mounjaro. “With costs increasing, patients are turning to online platforms. But fake treatments are highly risky. You can’t be certain what’s contained or whether the environment they were made in was clean,” she explained.
Her staff has previously encountered individuals injured by self-injection from unverified sources. “We recognize the frustration, but purchasing from messaging apps or communication platforms is gambling with your health,” said the doctor. “These materials could be impure or improperly measured.”
Manufacturer Statement
A spokesperson from the pharmaceutical company stated the substance was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Therefore at this time no one can sell [it] for human use,” they said, adding that any product “falsely representing itself as a company experimental substance not yet authorized … may subject patients to possibly significant health risks”.
